Preliminary data from a phase 1/2 trial indicate that Principia Biopharma’s BTK inhibitor Rilzabrutinib could treat immune thrombocytopenia.
Celldex Therapeutics’ CDX-0159, an inhibitor of the KIT receptor, led to sustained reductions in plasma tryptase levels in the phase 1 trial.
Calquence (Acalabrutinib), Astrazeneca’s bruton tyrosine kinase inhibitor, is thought to treat COVID-19 by suppressing lung macrophages.
Gilead and Galapagos NV announced the results of two phase 2 human trials evaluating filgotinib in adults with psoriatic arthritis.
Rights to the antibody candidate JTX-8064 have been transferred from Bristol-Myers Squibb back to Jounce Therapeutics effective June 3rd 2020.
Interim analysis of the ZUMA-5 trial found that Yescarta showed efficacy for treating relapsed or refractory indolent non-hodgkin lymphoma.
T-COVID is anticipated to provide clinical benefit to COVID-19 patients that are not yet hospitalized in the phase 1/2 clinical trial.
AB201, a potential protein-based treatment for blood clotting related to COVID-19, will be developed by ARCA Biopharma towards the clinic.
The NDA submission is intended to support the approval of Tivozanib as a treatment for adult renal cell carcinoma in the United States.